Prognostic significance of peripheral blood and bone marrow infiltration in newly-diagnosed canine nodal marginal zone lymphoma by L. Marconato et al.
 1 
Original article 1 
 2 
Prognostic significance of peripheral blood and bone marrow infiltration in newly-3 
diagnosed canine nodal marginal zone lymphoma 4 
 5 
Laura Marconato a,*, Stefano Comazzi b, Luca Aresu c, Fulvio Riondato c, Damiano Stefanello 6 
b, Roberta Ferrari b, Valeria Martini b 7 
 8 
 9 
a Centro Oncologico Veterinario, via San Lorenzo 1-4, 40037 Sasso Marconi (BO), Italy 10 
b Department of Veterinary Medicine, University of Milan, Via Celoria 10, 20133, Milan, Italy 11 
c Department of Veterinary Sciences, University of Turin, Largo P. Braccini 2, 10095 Grugliasco, 12 
Turin, Italy   13 
 14 
 15 
 16 
* Corresponding author. Tel.: 0039 051 6751871 17 
 E-mail address: marconato@centroncologicovet.it (L. Marconato) 18 
 19 
  20 
 2 
Abstract 21 
Canine nodal marginal zone lymphoma (nMZL) is infrequent and is typically 22 
diagnosed at an advanced disease stage. However, it is currently unknown whether different 23 
levels of peripheral blood (PB) and bone marrow (BM) infiltration may provide prognostic 24 
stratification in dogs with nMZL. 25 
The aims of the present prospective study were to assess the influence of PB and BM 26 
infiltration detected by flow cytometry (FC) on time to progression (TTP) and lymphoma-27 
specific survival (LSS) in dogs with newly-diagnosed multicentric nMZL, and to establish a 28 
cut-off value of prognostic significance.  29 
Forty-five completely staged and treatment-naïf dogs with histologically-confirmed 30 
nMZL were enrolled. After staging, dogs received chemo-immunotherapy or chemotherapy. 31 
PB infiltration was significantly associated with TTP (p=0.001): dogs with PB infiltration 32 
<30% had a median TTP of 186 days, whereas dogs with PB infiltration ≥30% had a median 33 
TTP of 43 days. Additionally, vaccinated dogs had a significantly (p=0.012) longer TTP (399 34 
days) compared with dogs receiving chemotherapy only (211 days). 35 
BM infiltration was significantly associated with LSS (p<0.001): dogs with BM 36 
infiltration <1% had a median LSS of 1403 days, those with BM infiltration 1-20% of 337 37 
days, and those with BM infiltration ≥20% of 188 days. Normal LDH levels and the 38 
administration of chemo-immunotherapy also significantly improved LSS (560 vs 211 days, 39 
and 399 vs 211 days, respectively; p<0.001). 40 
PB and BM flow cytometric evaluation is an integral part of staging work-up in dogs 41 
with nMZL and has prognostic relevance. 42 
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Introduction 47 
In dogs, nodal marginal zone lymphoma (nMZL) is infrequent, representing 48 
approximately 10% of all lymphoma histotypes diagnosed in this species (Valli et al., 2011). 49 
It was recently documented that nMZL is characterized by generalized lymphadenopathy and 50 
is diagnosed at an advanced disease stage; thus, despite the indolent designation, the 51 
prognosis is guarded (Cozzi et al., 2018). 52 
Adequate management of canine lymphoma requires accurate histological diagnosis 53 
and comprehensive staging, which includes assessment of bone marrow (BM) involvement. 54 
Therapeutic options rely mainly on the results of these procedures (Marconato et al., 2017). 55 
 56 
In dogs with diffuse large B-cell lymphoma (DLBCL), it has been shown that 3% BM 57 
infiltration evaluated by flow cytometry (FC) identified cases with an unfavorable prognosis 58 
(Marconato et al., 2013). According to a recent study, peripheral blood (PB) and BM 59 
infiltration occurred in 97.1% and 57.1% of canine nMZL cases, respectively (Cozzi et al., 60 
2018). However, it is currently unknown whether different levels of PB and BM infiltration 61 
may provide prognostic stratification in dogs with nMZL. 62 
 63 
The aims of the present prospective study were to assess the influence of different 64 
levels of PB and BM infiltration, detected by FC, on the duration of the first remission and 65 
survival in dogs with newly-diagnosed multicentric nMZL, and to establish a cut-off value of 66 
prognostic significance. 67 
 68 
Material and methods 69 
Inclusion criteria 70 
A prospective analysis of dogs with multicentric nMZL was performed. To be enrolled 71 
in the study, dogs were required to have complete clinicopathological data for analysis, and be 72 
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treatment-naïf. Corticosteroids before admission were permitted.  73 
 74 
All dogs were staged according to the World Health Organization system (Owen, 75 
1980), comprising history, physical examination, haematology, serum biochemistry 76 
(including serum lactate dehydrogenase, LDH), thoracic radiographs, abdominal ultrasound, 77 
and cytological evaluation of a fine-needle aspirate of an enlarged peripheral lymph node 78 
(LN). Dogs also underwent LN, PB and BM sampling for FC evaluation, and 79 
lymphadenectomy of an enlarged peripheral LN, having histopathological evaluation and 80 
immunohistochemistry (CD3, CD20) as a part of their initial staging work-up (Aresu et al, 81 
2015). The same LN that was aspirated for obtaining a cytological diagnosis and for FC was 82 
then surgically removed. The diagnosis of nMZL late-stage was confirmed according to the 83 
WHO classification (Valli et al., 2011).  84 
For the specific aims of the present research, at the end of the study, FC data were 85 
blindly re-analyzed to minimize possible interpretation biases among different readers over 86 
time. Only the re-analyzed results have been considered for the study. 87 
 88 
The care of the dogs enrolled in the study was in accordance with institutional 89 
guidelines. All owners provided written informed consent. 90 
 91 
Flow cytometry 92 
Flow cytometric immunophenotyping was performed on LN aspirates obtained with 93 
22-gauge needles and collected in tubes containing RPMI1640 (Sigma Aldrich) and on PB 94 
and BM samples collected into EDTA tubes. All samples were kept refrigerated and 95 
processed within 24h of sampling. A panel of antibodies was used for LN labeling using a 96 
multi-colour approach as previously described (Gelain et al., 2008), and included: CD45 97 
(clone YKIX716.13, pan-leukocyte), CD5 (clone YKIX322.3, T-cells), CD21 (clone 98 
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CA2.1D6, B-cells), and CD34 (clone 1H6, precursor cells). PB and BM samples were stained 99 
with CD45, CD5 and CD21 antibodies. All antibodies but CD34 were provided by Bio-Rad 100 
(formerly AbD Serotec; Oxford, UK); CD34 was provided by BD Pharmingen (San Diego, 101 
CA, USA). Erythrocyte lysis was not necessary on LN samples, since haemodilution was 102 
minimal, and double labeling using CD45 easily enabled the distinction between lymphoid 103 
cells and debris or erythrocytes. Conversely, erythrocyte lysis was performed on PB and BM 104 
samples by means of an erythrocyte lysis buffer containing 8% ammonium chloride, after 105 
incubation with antibodies. All samples were acquired with a BD FACScalibur flow 106 
cytometer (Becton Dickinson, San Josè, CA, USA) and analyzed with CellQuest software 107 
(Becton Dickinson). 108 
 109 
Determination of PB and BM involvement 110 
PB and BM aspirates were obtained in all cases at the time of the initial staging work-111 
up. BM was sampled with 16- or 18-gauge Illinois needles from the iliac crest. PB and BM 112 
samples were placed in EDTA tubes for FC analysis. 113 
The extent of PB and BM infiltration by large B-cells was reported as the percentage 114 
of medium-large CD21-positive cells out of the total CD45-positive cells (leucocytes and 115 
their precursors). The threshold for cell size was set based on the FSC of non-neoplastic T-116 
lymphocytes from the same subject. Normal circulating B-cells show the lowest FSC among 117 
lymphocytes, being smaller than normal T-cells. Reactive medium-sized B-cells present FSC 118 
properties partially overlapping those of T-cells. Thus, most of reactive medium-sized B-cells 119 
were not included in the count of infiltrating neoplastic cells with our gating strategy.  120 
 121 
Treatment and response evaluation 122 
The treatment protocol was in keeping with approved standards. Dogs whose owners 123 
wished to pursue immunotherapy received a 20-week dose-intense chemotherapy regimen, 124 
 6 
consisting of L-Asparaginase, Vincristine, Cyclophosphamide, Doxorubicin, Lomustine, and 125 
prednisone (Table 1). These dogs also received an intradermal injection of 0.5 ml autologous 126 
vaccine on weeks 4, 5, 6, 7, 12, 16, 20, and 24, as previously described (Marconato et al., 127 
2014). 128 
Dogs treated with chemotherapy only, received the following protocol, consisting of 129 
L-Asparaginase, Vincristine, Cyclophosphamide, Doxorubicin, Lomustine, and Prednisone  130 
(Table 1). 131 
Response was classified as complete remission (CR), partial remission (PR), stable disease 132 
(SD), or progressive disease (PD) based on previously published criteria (Marconato et al., 133 
2013). Responses were required to last for ≥ 28 days. 134 
 135 
Relapse was defined as clinical reappearance and cytological evidence of lymphoma in 136 
any anatomical site in dogs having experienced CR, whereas relapse for animals with PR was 137 
defined as progression. 138 
Response was evaluated at each chemotherapy session by measurement of peripheral 139 
LNs. End-staging was carried out at the end of treatment, and every clinical, radiological, 140 
ultrasonographic, or laboratory investigation that disclosed abnormalities at pre-treatment 141 
staging was repeated. BM and PB were re-evaluated in all cases by FC. The end-staging 142 
results were necessary to assess treatment response. 143 
 144 
Statistical analysis 145 
Time to progression (TTP) was calculated from the start of treatment to disease 146 
progression (Vail et al., 2010). Dogs lost to follow-up or dead for lymphoma-unrelated causes 147 
before disease progression, as well as those in CR at the end of the study, were censored for 148 
TTP analysis. 149 
Lymphoma-specific survival (LSS) was measured as the interval between the start of 150 
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treatment and death for lymphoma (Vail et al., 2010). Dogs alive at the end of the study, lost 151 
to follow-up or dead due to causes other than lymphoma were censored for LSS analysis. 152 
 153 
To detect possible associations between TTP and LSS, and PB and BM infiltration, 154 
cases were subdivided into two groups based on the arbitrarily selected infiltration cut-offs of 155 
1.0%, 3.0%, 5.0%, 10.0%, 20.0% and 30.0%. Thereafter, Kaplan-Meier curves were drawn 156 
for each cut-off and compared using the log-rank test. Based on data distribution, the 30.0% 157 
cut-off was not tested on BM samples. As two different BM cut-offs gave significant results 158 
for LSS analysis, these were coupled to stratify the study population into three groups, which 159 
were further tested by Kaplan-Meier curves and log-rank test. 160 
 161 
Univariate Cox’s proportional hazard regression analysis was performed to determine 162 
a possible association between selected variables and TTP and LSS, respectively. Variables 163 
with p≤0.3 at univariate analysis were then included in a backward elimination multivariate 164 
analysis. For categorical variables, Kaplan-Meier curves were drawn and compared by log-165 
rank test. 166 
 167 
The independent variables included in the analyses were: breed (pure or mixed), age 168 
(< or ≥ 8 years), sex (male or female), weight (< or ≥ 22.5 kg), clinical stage (I-V), substage 169 
(a or b), anemia (presence or absence), thrombocytopenia (presence or absence), LDH (within 170 
or outside the reference interval [0-170 U/I]), FC PB infiltration (%), PB infiltration group 171 
(<30% or ≥30%), FC BM infiltration (%), BM infiltration group (<1%, 1%-20%, or ≥20%), 172 
therapy (chemotherapy or chemo-immunotherapy). 173 
Possible differences in the aforementioned variables between the two treatment groups 174 
were investigated with Pearson chi-squared test (for categorical variables) or with Mann-175 
Whitney test (for continuous, non-parametric variables). 176 
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 177 
All analyses were performed with a standard software (SPSS v20.0 for Windows), and 178 
significance was set at p≤0.05 for all analyses. 179 
 180 
Results 181 
Between 2011 and 2018, 45 cases met the inclusion criteria and were enrolled. There 182 
were 12 (26.7%) mixed-bred and 33 (73.3%) pure-breed dogs. Among these, there were 3 183 
Rottweiler, 3 Poodle, 2 jack russel terrier, 2 Australian shepherd, 2 Pomeranian, 2 Golden 184 
retriever, 2 German shepherd, 2 French Bulldog, 2 Labrador retriever, and one each of the 185 
following: Bassethound, dachshund, shih-tzu, beagle, Petit Bleu, Yorkshire terrier, Border 186 
collie, Bernese Mountain dog, Pinscher, Akita Inu, Dobermann, Boxer, and German Hound. 187 
Twenty (44.4%) dogs were females (11 spayed) and 25 (55.6%) were males (3 188 
neutered). Mean age was 7.9±3.2 years (median 8 years, range 3-15 years), with 21 (46.7%) 189 
dogs being <8 year-old and 24 (53.3%) ≥8 year-old. Mean body weight was 22.5±12.5 kg 190 
(median 24.4 kg, range 3.0-44.4 kg); the body weight was <22.5 kg in 21 (46.7%) dogs and 191 
≥22.5 kg in 24 (53.3%). 192 
One (2.2%) dog had stage IIIa disease, 6 (13.3%) had stage IV disease (4 substage a, 2 193 
substage b), and 38 (84.4%) had stage V disease (24 substage a, 14 substage b). Anemia and 194 
thrombocytopenia were present in 4 (8.9%) and 6 (13.3%) dogs, respectively. LDH activity 195 
was tested in 41 dogs and was increased in 17 (41.5%). 196 
 197 
Mean PB infiltration at diagnosis was 10.43±12.82% (median 5.0%, range 0.2-53.5%). 198 
It was <1% in 8 (17.8%) dogs, <3% in 15 (33.3%), <5% in 20 (44.4%), <10% in 32 (31.1%), 199 
<20% in 36 (80.0%), <30% in 41 (91.1%), and ≥30% in 4 (8.9%). 200 
Mean BM infiltration at diagnosis was 6.86±9.39% (median 3.0%, range 0.2-51.6%). 201 
It was <1% in 9 (20.0%) dogs, <3% in 22 (48.9%), <5% in 25 (55.6%), <10% in 36 (80.0%), 202 
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<20% in 42 (93.3%), <30% in 44 (97.8%), and ≥30% in 1 (2.2%). 203 
 204 
Twenty-four (53.3%) dogs received chemo-immunotherapy, and 21 (46.7%) were 205 
treated with chemotherapy. Twenty (83.3%) of 24 dogs treated with chemo-immunotherapy 206 
and 13 (61.9%) of 21 dogs treated with chemotherapy achieved CR, confirmed by a complete 207 
end-staging. However, 17 (85%) of the 20 dogs treated with chemo-immunotherapy and all 208 
(100%) dogs treated with chemotherapy eventually relapsed. 209 
The two treatment cohorts were homogeneous for all investigated variables. 210 
 211 
Median TTP was 179 days (range, 1-1295 days). In particular, 40 (88.9%) dogs 212 
progressed during the study period, whereas 4 (8.9%) died for lymphoma-unrelated causes 213 
after 93, 151, 181 and 237 days, respectively, and one (2.2%) dog was still alive and in CR 214 
after 1295 days. 215 
Median LSS was 337 days (range, 5-1403 days). In particular, 33 (73.3%) dogs died 216 
for their lymphoma during the study period, 8 (17.8%) were still alive at data analysis closure 217 
with a median follow-up of 701 days (range 281-1295 days), and 4 (8.9%) died for 218 
lymphoma-unrelated causes after 93, 151, 181 and 237 days, respectively. 219 
 220 
The results obtained for the different PB and BM infiltration cut-offs are shown in 221 
Table 2. According to these results, cases were subdivided into two PB infiltration groups 222 
(<30% and ≥30%) and into three BM infiltration groups (<1%, 1-20%, and ≥20%). 223 
 224 
Concerning TTP, univariate Cox’s analysis and log-rank test gave significant results 225 
for substage (p=0.020 and p=0.017, respectively), treatment (p=0.037 and p=0.033, 226 
respectively) and PB infiltration groups (p=0.006 and p=0.002, respectively) (Fig 1). 227 
Multivariate analysis showed significant results for treatment (p=0.012) and PB infiltration 228 
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groups (p=0.001).  229 
Median TTP for significant variables is shown in Table 3. 230 
 231 
Concerning LSS, univariate Cox’s analysis and log-rank test gave significant results 232 
for substage (p=0.002 and p=0.001, respectively), LDH (p=0.050 and p=0.044, respectively), 233 
PB infiltration groups (p=0.015 and p=0.008, respectively) and BM infiltration groups 234 
(p=0.035 and p=0.022, respectively) (Fig 2). Multivariate analysis gave significant results for 235 
LDH (p<0.001), treatment (p=0.002) and BM infiltration groups (p<0.001). In particular, 236 
dogs with BM infiltration <1% had a median LSS of 1403 days, whereas dogs with BM 237 
infiltration of 1-20% and ≥20% had a median LSS of 337 and 188 days, respectively. 238 
Median LSS for significant variables is shown in Table 4. 239 
 240 
Discussion 241 
Recent advances in imaging and laboratory methodology have the potential to improve 242 
disease characterization and outcome in dogs with lymphoma, possibly leading to changes in 243 
clinical practice and, eventually, in trial design. PB and BM evaluation is part of the staging 244 
work-up for canine lymphoma, and FC is essential to detect and quantify their involvement 245 
(Riondato et al., 2016; Riondato et al., 2017). However, knowledge about the prognostic value 246 
of PB and BM infiltration based on FC in canine nMZL is limited.  247 
The results of the current study suggest, in a homogeneous series of 45 dogs with 248 
newly-diagnosed nMZL late-stage, that PB and BM infiltration detected by FC at diagnosis is 249 
frequent and influences the duration of first remission and survival.  250 
PB involvement in nMZL as detected by FC significantly influenced TTP. The 251 
presence of circulating neoplastic cells was related to clinical stage and BM involvement, and 252 
correlated with poor disease control. Indeed, dogs with <30% PB involvement had a median 253 
TTP of 186 days, whereas dogs with ≥30% PB involvement relapsed earlier (TTP 43 days). 254 
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Lymphoma cells in PB reflect the biological property of entry of solid tumor cells into the 255 
circulation. Relapse is due either to incomplete remission in dogs with extensive tumor 256 
burden or to chemoresistance. Dogs with marked (≥30%) PB involvement had a very short 257 
remission; therefore, it may be possible that these cells were chemoresistant or had 258 
temporarily resided at sites poorly accessible to chemotherapy. 259 
It has been previously documented that indolent B-cell lymphoma appears to be 260 
associated with a higher incidence of BM infiltration compared with aggressive B-cell 261 
lymphoma (33-80% versus 18-27%, respectively) (Aresu et al, 2015; Marconato et al., 2015a, 262 
Cozzi et al., 2018), thereby confirming the need for extensive staging in all lymphoma cases. 263 
Indeed, dogs with nMZL showed a heterogeneous clinical course based on BM infiltration, 264 
which resulted to be an independent predictor for LSS. Dogs with BM infiltration <1% had a 265 
significantly longer survival time compared with dogs with BM infiltration in the range of 1-266 
20% and ≥20%. Moreover, despite the overall poor treatment outcomes in nMZL cases with 267 
BM infiltration, dogs with less extent of BM infiltration (1-20%) had a more favorable 268 
outcome compared with dogs in the other group (12 months versus 6 months, respectively), 269 
stressing the need not only for the detection of marrow involvement, but also for neoplastic 270 
cell quantification.  271 
Beside PB and BM involvement, further variables were independent predictive factors 272 
in multivariate analysis.  273 
An elevated LDH activity at initial diagnosis was predictive for shorter survival. This 274 
is in agreement with a previous study, whereby it was shown that elevated LDH activity was 275 
more frequent in dogs with DLBCL and higher PB and BM infiltration, possibly indicating a 276 
marked disease activity. Also, in the same study, high LDH activity predicted a more 277 
aggressive clinical course (Marconato et al., 2013). The same may hold true for nMZL. 278 
Dogs receiving chemo-immunotherapy had a significantly longer TTP and LSS 279 
compared with dogs treated with chemotherapy only. In a previous study (Marconato et al., 280 
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2014), chemo-immunotherapy significantly improved TTP in dogs with indolent B-cell 281 
lymphoma when compared to dogs receiving chemotherapy only, whereas LSS only tended to 282 
be longer. The differences between these studies might be explained by sample size and the 283 
different enrollment criteria, because the earlier study included all subtypes of indolent 284 
lymphoma as one entity instead of individual subtypes.  285 
Interestingly, when comparing BM infiltration data with the ones previously published 286 
in DLBCL (Marconato et al., 2013), a better stratification for TTP and LSS was obtained in 287 
dogs with nMZL. This result is also emphasized by the diagnostic and biological limits that 288 
have been described so far for these two histotypes. Indeed, the histological diagnosis of 289 
nMZL late-stage is still a conundrum because of the lack of immunohistochemical markers 290 
that allow in many cases distinguishing it from DLBCL. To rule out this risk, we included 291 
only nMZLs that were histologically characterized by a diffuse infiltration of neoplastic cells 292 
with intermediate-sized nuclei, prominent single central nucleoli, abundant lightly stained 293 
cytoplasm, low mitotic rate and absence of centroblasts and immunoblasts. Moreover, two 294 
gene expression profile studies have recently shown that nMZL and DLBCL are similar at the 295 
transcriptomic level (Frantz et al., 2013), but they result two separate entities clinically, 296 
suggesting other biological mechanisms underlying tumor cells of origin. 297 
This study has some limitations.  298 
First, there was treatment regimens heterogeneity in the population of our study. 299 
Approximately 50% of dogs received an autologous vaccine in addition to conventional 300 
chemotherapy. Analyses of prognostic factors for TTP and LSS showed a better outcome for 301 
dogs that received chemo-immunotherapy. As of today, there are no standard recommended 302 
treatments for nMZL, which has not proven curable with classical chemotherapy (Aresu et al, 303 
2015, Marconato et al., 2015b). In the current study, the combination of chemotherapy and 304 
immunotherapy significantly improved outcome. This finding raises the question as to 305 
possible choices in terms of classical chemotherapy and whether immunotherapy should be 306 
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the new gold standard for first-line treatment in dogs with nMZL. 307 
Second, the FC strategy used to quantify PB and BM infiltration in the present study 308 
has never been validated for canine nMZL, but was derived by the one used to stage canine 309 
large B-cell lymphomas (Riondato et al., 2016). In particular, we lowered the FSC threshold 310 
in order to include medium-sized cells in the count. This likely affects the analytical and 311 
diagnostic performances reported. In particular, the limit of detection (LOD) of medium-large 312 
CD21+ cells in non-neoplastic samples is likely higher than the one reported for large B-cells, 313 
and even higher than 1%. Nevertheless, we report relevant prognostic implications only for 314 
highly infiltrated BM samples (>20%), which is likely far from the LOD of the technique, and 315 
for samples with <1% infiltration, where neoplastic cells are virtually absent. Cases 316 
potentially located between 1% and LOD would fall in the limbo of the 1-20% BM infiltration 317 
group, which bears an intermediate prognosis and warrants examination of further prognostic 318 
parameters. 319 
 320 
Conclusions 321 
The detection of PB and BM involvement in most dogs with nMZL confirms the need 322 
for PB and BM flow cytometric evaluation as an integral part of staging work-up also in these 323 
patients. We found that PB infiltration ≥30% and BM infiltration ≥20% in dogs with nMZL 324 
are independent negative prognostic factors. More specifically, in dogs with PB infiltration 325 
<30%, BM evaluation stratifies dogs into 3 prognostic groups: those with a poor (infiltration 326 
≥20%), intermediate (infiltration 1-20%) and better (infiltration <1%) prognosis. 327 
Future efforts should be directed toward finding optimal treatment modalities in 328 
managing nMZL dogs based on the extent of PB and BM infiltration.  329 
 330 
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Table   1 405 
Therapeutic protocols administered to 45 dogs with Marginal Zone Lymphoma (MZL) 406 
 Week number 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
Chemo-immunotherapy protocol 
L-ASP X                   
VCR  X X X         X       
CYCLO  X           X       
DOXO       X         X    
CCNU          X         X 
 Prednisolone administered at 1 mg/kg daily from week 1 to week 4; then 0.5 mg/kg daily until the end of treatment 
Chemotherapy protocol 
L-ASP X                   
VCR  X   X      X      X   
CYCLO   X   X      X      X  
DOXO    X   X      X      X 
CCNU         X      X     
 Prednisolone administered at 1 mg/kg daily from week 1 to week 4; then 0.5 mg/kg daily until the end of treatment 
 17 
L-ASP = L-asparaginase (400 UI/kg SQ); VCR = Vincristine (0.75 mg/m2 IV); CYCLO = Cyclophosphamide (250 mg/m2 PO in the chemo-407 
immunotherapy protocol,  75 mg/m2 PO for 4 consecutive days in the chemotherapy protocol); DOXO = Doxorubicin (30 mg/m2 IV); CCNU = 408 
Lomustine (80 mg/m2 PO)409 
 18 
Table 2 410 
P-values obtained by comparing Kaplan-Meier curves using different arbitrarily selected cut-offs 411 
for peripheral blood and bone marrow infiltration in 45 dogs diagnosed with Marginal Zone 412 
Lymphoma. 413 
Matrix Cut-off Log-rank test p-value 
Time to progression Lymphoma specific survival 
Peripheral blood 1% 0.416 0.419 
3% 0.515 0.614 
5% 0.315 0.463 
10% 0.510 0.824 
20% 0.183 0.572 
30%§ 0.002* 0.008* 
Bone marrow 1% 0.098 0.039* 
3% 0.155 0.102 
5% 0.241 0.258 
10% 0.188 0.237 
20% 0.092 0.044* 
1% and 20%§ 0.077 0.022* 
*= significant result; §= cutoff selected for further survival analyses 414 
 415 
  416 
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Table 3 417 
Time to progression (TTP) in 45 dogs with nodal Marginal Zone Lymphoma, according to specific 418 
variables 419 
Variable 
(number of dogs) 
Median 
TTP in days 
(range) 
P-value Hazard ratio 
(95% CI) Univariate 
analysis 
Log-
rank 
test 
Multivariate 
analysis 
Substage  0.020* 0.017* 0.930  
a (29) 312 
(24-1295) 
   Ref 
b (16) 60 
(1-420) 
   2.195 (1.131-4.263) 
Therapy  0.037* 0.033* 0.012*  
Chemotherapy (21) 78 
(1-1295) 
   1.950 (1.040-3.658) 
Chemo-
immunotherapy 
(24) 
227 
(29-720) 
   Ref 
PB infiltration  0.006* 0.002* 0.001*  
<30% (41) 186 
(1-1295) 
   Ref 
≥30% (4) 43 
(1-134) 
   4.897 (1.579-15.188) 
*=significant result 420 
 421 
  422 
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Table 4 423 
Lymphoma specific survival (LSS) in 45 dogs with nodal Marginal Zone Lymphoma, according to 424 
specific variables. 425 
Variable 
(number of 
dogs) 
Median LSS 
in days 
(range) 
P-value Hazard ratio 
(95% CI) Univariate 
analysis 
Log-rank 
test 
Multivariate 
analysis 
Substage  0.002* 0.001* 0.905  
a (29) 544 
(93-1403) 
   Ref 
b (16) 125 
(5-862) 
   3.375 (1.572-7.247) 
Therapy  0.093 0.088 0.002*  
Chemotherapy 
(21) 
211 
(5-1403) 
   1.833 (0.905-3.714) 
Chemo-
immunotherapy 
(24) 
399 
(93-1321) 
   Ref 
PB infiltration  0.015* 0.008* 0.175  
<30% (41) 349 
(5-1403) 
   Ref 
≥30% (4) 125 
(7-215) 
   4.017 (1.314-12.283) 
LDH activity  0.050* 0.044* <0.001*  
Normal (24) 560 
(111-1403) 
   Ref 
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Increased (17) 211 
(7-730) 
   2.172 (1.002-4.710) 
BM infiltration  0.035* 0.022* <0.001*  
<1% (9) 1403 
(45-1403) 
   Ref 
1%-20% (33) 337 
(5-1321) 
   2.754 (0.948-7.997) 
≥20% (3) 188 
(7-215) 
   7.771 (1.621-37.244) 
*=significant result 426 
  427 
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Fig. 1. Kaplan-Meier curves representing time to progression of 45 dogs with nodal Marginal Zone 428 
Lymphoma with <30% (continuous line) or ≥30% (dotted line) peripheral blood flow cytometric 429 
infiltration. 430 
 431 
Fig. 2. Kaplan-Meier curves representing lymphoma specific survival of 45 dogs with nodal 432 
Marginal Zone Lymphoma with <1% (continuous line), 1-20% (dashed line) or ≥20% (dotted line) 433 
bone marrow flow cytometric infiltration. 434 
 435 
